JP2014509851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509851A5 JP2014509851A5 JP2013557704A JP2013557704A JP2014509851A5 JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5 JP 2013557704 A JP2013557704 A JP 2013557704A JP 2013557704 A JP2013557704 A JP 2013557704A JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5
- Authority
- JP
- Japan
- Prior art keywords
- npp1
- fusion protein
- npp1 fusion
- acid residues
- targeting moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150011046 NPP1 gene Proteins 0.000 claims 44
- 101100080092 Phytophthora capsici NLP1 gene Proteins 0.000 claims 44
- 102000037865 fusion proteins Human genes 0.000 claims 37
- 108020001507 fusion proteins Proteins 0.000 claims 37
- 230000008685 targeting Effects 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 230000003197 catalytic effect Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 102000009609 Pyrophosphatases Human genes 0.000 claims 2
- 108010009413 Pyrophosphatases Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34006610P | 2010-03-12 | 2010-03-12 | |
| USPCT/US2011/028233 | 2011-03-11 | ||
| PCT/US2011/028233 WO2011113027A2 (en) | 2010-03-12 | 2011-03-11 | Npp1 fusion proteins |
| PCT/US2011/051858 WO2012125182A1 (en) | 2011-03-11 | 2011-09-15 | Npp1 fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015084216A Division JP6096826B2 (ja) | 2010-03-12 | 2015-04-16 | Ｎｐｐ１融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509851A JP2014509851A (ja) | 2014-04-24 |
| JP2014509851A5 true JP2014509851A5 (enExample) | 2014-11-06 |
| JP5735665B2 JP5735665B2 (ja) | 2015-06-17 |
Family
ID=44564171
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557704A Active JP5735665B2 (ja) | 2010-03-12 | 2011-09-15 | Ｎｐｐ１融合タンパク質 |
| JP2015084216A Active JP6096826B2 (ja) | 2010-03-12 | 2015-04-16 | Ｎｐｐ１融合タンパク質 |
| JP2017026961A Active JP6484905B2 (ja) | 2010-03-12 | 2017-02-16 | Ｎｐｐ１融合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015084216A Active JP6096826B2 (ja) | 2010-03-12 | 2015-04-16 | Ｎｐｐ１融合タンパク質 |
| JP2017026961A Active JP6484905B2 (ja) | 2010-03-12 | 2017-02-16 | Ｎｐｐ１融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US8846603B2 (enExample) |
| EP (1) | EP2545080B1 (enExample) |
| JP (3) | JP5735665B2 (enExample) |
| BR (1) | BR112013023010B1 (enExample) |
| CL (1) | CL2013002607A1 (enExample) |
| ES (2) | ES2628841T3 (enExample) |
| NZ (1) | NZ615070A (enExample) |
| SG (2) | SG10202100341XA (enExample) |
| TR (1) | TR201903573T4 (enExample) |
| WO (1) | WO2011113027A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011113027A2 (en) | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
| RU2550961C2 (ru) | 2010-09-09 | 2015-05-20 | Синаджева Биофарма Корп. | Использование кислой лизосомной липазы для лечения дефицита кислой лизосомной липазы у больных |
| KR20140006037A (ko) | 2011-02-15 | 2014-01-15 | 시나게바 바이오파르마, 코포레이션 | 리소좀의 산 리파제 결핍을 치료하는 방법들 |
| AU2011362576B2 (en) * | 2011-03-11 | 2017-06-08 | Alexion Pharmaceuticals, Inc. | NPP1 fusion proteins |
| PL2956163T3 (pl) | 2013-02-13 | 2025-04-14 | Yale University | Kompozycje do leczenia patologicznego zwapnienia i kostnienia |
| EP3399317A1 (en) * | 2013-05-06 | 2018-11-07 | Bio-rad Laboratories, Inc. | Stabilization of labile analytes in reference materials |
| WO2016100803A2 (en) | 2014-12-19 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
| MX391074B (es) | 2015-05-19 | 2025-03-21 | Univ Yale | Composiciones para el tratamiento de condiciones patológicas de calcificación y sus métodos de uso. |
| CA3005142A1 (en) | 2015-11-20 | 2017-05-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
| EP3471747A1 (en) * | 2016-06-16 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| EP3493829B1 (en) | 2016-08-05 | 2024-04-17 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| AU2019327572B2 (en) | 2018-08-31 | 2025-11-13 | Yale University | ENPP1 polypeptides and methods of using same |
| KR20230042263A (ko) | 2020-06-09 | 2023-03-28 | 이노자임 파마, 인코포레이티드 | 가용성 enpp1 또는 enpp3 단백질 및 이의 사용 |
| WO2025184419A1 (en) * | 2024-02-29 | 2025-09-04 | Kodiak Sciences Inc. | Engineered complement inhibitor proteins |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
| US6455495B1 (en) | 1997-02-14 | 2002-09-24 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| US20040019923A1 (en) | 1997-10-16 | 2004-01-29 | Ivarie Robert D. | Exogenous proteins expressed in avians and their eggs |
| JP2001520009A (ja) | 1997-10-16 | 2001-10-30 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | 鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター |
| DK1032662T3 (da) | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulation |
| DE20121960U1 (de) | 2000-04-06 | 2004-01-15 | Epigenomics Ag | Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten |
| US20020108132A1 (en) | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
| AU2003213246A1 (en) | 2002-02-21 | 2003-09-09 | University Of Virginia Patent Foundation | Bone targeting peptides |
| US20050090001A1 (en) | 2003-10-07 | 2005-04-28 | Parker Stephen H. | Cell lines and methods for producing proteins |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
| US20090180989A1 (en) * | 2005-10-05 | 2009-07-16 | Synageva Biopharma Corp. | Compositions and methods for delivering nucleotide sequences to vertebrates |
| PL2158319T4 (pl) | 2007-05-11 | 2016-04-29 | Alexion Pharma Inc | Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie |
| PE20100141A1 (es) * | 2008-05-23 | 2010-02-22 | Wyeth Corp | Proteina de union al receptor de interleuquina 21 |
| WO2011113027A2 (en) | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
-
2011
- 2011-03-11 WO PCT/US2011/028233 patent/WO2011113027A2/en not_active Ceased
- 2011-03-11 EP EP11754231.6A patent/EP2545080B1/en active Active
- 2011-03-11 US US13/583,973 patent/US8846603B2/en active Active
- 2011-03-11 ES ES11754231.6T patent/ES2628841T3/es active Active
- 2011-09-15 SG SG10202100341XA patent/SG10202100341XA/en unknown
- 2011-09-15 BR BR112013023010-0A patent/BR112013023010B1/pt active IP Right Grant
- 2011-09-15 JP JP2013557704A patent/JP5735665B2/ja active Active
- 2011-09-15 NZ NZ615070A patent/NZ615070A/en not_active IP Right Cessation
- 2011-09-15 TR TR2019/03573T patent/TR201903573T4/tr unknown
- 2011-09-15 ES ES11861101T patent/ES2716526T3/es active Active
- 2011-09-15 US US14/004,294 patent/US20140154774A1/en not_active Abandoned
- 2011-09-15 SG SG10201500208SA patent/SG10201500208SA/en unknown
-
2013
- 2013-09-10 CL CL2013002607A patent/CL2013002607A1/es unknown
-
2014
- 2014-08-01 US US14/449,364 patent/US9540621B2/en active Active
- 2014-10-06 US US14/507,124 patent/US20150024460A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084216A patent/JP6096826B2/ja active Active
-
2017
- 2017-01-27 US US15/417,590 patent/US20170145393A1/en not_active Abandoned
- 2017-02-16 JP JP2017026961A patent/JP6484905B2/ja active Active
-
2020
- 2020-11-25 US US17/105,245 patent/US20210301268A1/en not_active Abandoned
-
2022
- 2022-08-11 US US17/819,065 patent/US20230129977A1/en not_active Abandoned